Altimmune Inc.

Altimmune Inc. is a clinical‑stage biopharma developing a Phase 3 dual GLP‑1/GLP‑1 agonist, pemvidutide, for obesity/NASH and a suite of intranasal vaccines (AdCOVID, NasoShield) targeting COVID‑19 and anthrax.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 59
HQ: Gaithersburg

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
ALT	Altimmune Inc. Cap: 0.4B	EQUITY	NGM	USD	US02155H2004	Active	📈